UNSPSC 51434915: Bendroflumethiazide/potassium chloride/rauwolfia serpentina

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434915 Bendroflumethiazide/potassium chloride/rauwolfia serpentina, a Commodity code, shows limited direct recent activity under its nominal classification; state and local governments soliciting under this code are primarily acquiring advanced life support medications, emergency pharmaceutical supplies, and multi-source generic pharmaceuticals for public health systems, fire rescue services, and state health benefit programs. The Tampa Fire Rescue procurement illustrates the operational scope: sealed-bid acquisition of specific medication line items (Labetalol, Epinephrine, Adenosine, and Diltiazem) with expiration-date floors, delivery windows, and warranty periods. Beyond single-commodity acquisitions, state health and human services agencies are also using related procurement vehicles to establish broader pharmaceutical supply relationships, such as the Texas HHS Commission's direct-to-manufacturer initiative and cooperative purchasing consortia agreements. Issuing bodies include municipal fire departments, state health and human services commissions, and multistate cooperative purchasing alliances serving state agencies and local health systems.

Recent activity spans Florida, Texas, and Minnesota, with the most concrete opportunity appearing in the City of Tampa's April 2026 sealed-bid for advanced life support medications (Solicitation 26P00188, response deadline April 8, 2026, estimated value $40,000), which included a 5 percent Small Local Business Enterprise bid discount not to exceed $10,000 and required comprehensive accessibility documentation and OSHA-compliant Safety Data Sheets. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued a multi-award RFP (S1070000015802) due March 26, 2026, establishing contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, effective July 1, 2026. The Texas HHS Commission's Request for Information (HHS0017013, posted April 3, 2026) sought vendor capabilities for direct-to-manufacturer prescription fulfillment to inform future formal solicitation design, indicating emerging interest in supply-chain restructuring among state health programs.